Nobuyuki Katakami

Takarazuka, 6650827, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

Journal: Japanese journal of clinical oncology

Published: April 29, 2026

Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).

Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 11, 2026

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

Journal: Therapeutic advances in medical oncology

Published: November 24, 2025

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

Journal: Cancer science

Published: October 06, 2025

Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study.

Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study.

Journal: Cancer treatment and research communications

Published: August 21, 2025

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: April 19, 2025

Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001).

Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001).

Journal: Medical oncology (Northwood, London, England)

Published: March 18, 2025

Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).

Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 28, 2024

Case of a Pleomorphic Carcinoma Successfully Treated with Nivolumab and Ipilimumab

Case of a Pleomorphic Carcinoma Successfully Treated with Nivolumab and Ipilimumab

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 25, 2024

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan.

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan.

Journal: JTO clinical and research reports

Published: August 26, 2024

Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).

Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).

Journal: Japanese journal of clinical oncology

Published: May 30, 2024

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 20, 2024

Showing 1-12 of 150

Last Updated: 09/26/2026